サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1424066

先端医療医薬品（ATMP）CDMO市場、シェア、規模、動向、産業分析レポート：製品別、フェーズ別、適応症別、地域別、セグメント別予測、2024年～2032年

Advanced Therapy Medicinal Products CDMO Market Share, Size, Trends, Industry Analysis Report, By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others); By Phase; By Indication; By Region; Segment Forecast, 2024 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 116 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
先端医療医薬品（ATMP）CDMO市場、シェア、規模、動向、産業分析レポート：製品別、フェーズ別、適応症別、地域別、セグメント別予測、2024年～2032年
出版日: 2024年01月24日
発行: Polaris Market Research
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の先端医療医薬品（ATMP）CDMO市場規模は2032年までに262億7,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

人口の間で数多くの病気が進化し、慢性的な健康問題を一般的な医薬品で治すことができるようになったため、研究者や政府機関は遺伝子医療や細胞・組織療法への投資を余儀なくされています。この継続的な動向は、製薬企業が新しい治療法を革新するのに適した環境を促進し、新しい治療法の開発、試験、製造に必要なインフラを持つ組織の必要性を促し、開発・製造受託機関（CDMO）の支援を必要としています。

製薬業界を規制する政府のイニシアチブの高まりは、先端医療医薬品（ATMP）CDMO市場の成長機会に好影響を示しています。2023年9月、英国のCDMOであるRentschler Biopharma SEは、Medicines &Healthcare Products Regulatory Agencyから、バイオプロセスやcGMP生産を含む遺伝子治療用のアデノ随伴ウイルスベクター（AAV）を開発・供給する認可を取得しました。

健康問題の治療に向けて研究開発活動を拡大するための戦略的共同研究やパートナーシップの新興国市場は、ATMP CDMO市場にプラスの影響を与えています。Histocell社との提携により、Reprocell社は間葉系幹細胞から生成される高度な治療薬や医薬品を製造することになります。

細胞治療と遺伝子治療の生産は、市場で前向きな見通しを示しています。Gene, Cell, &RNA Therapy Landscape Reportによると、2023年第3四半期には、27の遺伝子治療、26のRNA治療、65の非遺伝子組み換え細胞治療が臨床使用の承認を受けた。第1相臨床試験を実施中の遺伝子治療薬の総数は、第3四半期は第1四半期と比較して7％増加しました。この動向は、先端医療医薬品を製造する潜在的な需要を示しており、今後数年間のCDMOの必要性を高めています。

組織工学産業はマーケットプレースで勢いを増しています。その原動力は、組織の置換、修復、再生におけるその深い範囲であり、皮膚、心臓、肝臓、肺組織関連の健康問題の治療に使用されています。組織工学的治療法の開発に関する研究活動の高まりが、先端治療薬CDMO市場を牽引すると期待されています。

先端医療医薬品（ATMP）CDMO市場レポートハイライト

遺伝子治療に関する臨床試験の増加により、遺伝子治療分野は今後数年間で最も高い成長が見込まれます。

治療開発数の増加により、第i相市場が最大の収益シェアを占めました。

がん患者数の増加とその多様な形態により、がん領域が最大のシェアを占めました。

アジア太平洋地域は予測期間中に最も速い成長を記録すると予測されており、これは細胞治療と遺伝子治療への投資の増加に起因します。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の先端医療医薬品（ATMP）CDMO市場洞察

  • 先端医療医薬品（ATMP）CDMO市場- フェーズスナップショット
  • 先端医療医薬品（ATMP）CDMO市場力学
    • 促進要因と機会
      • バイオテクノロジーにおける細胞および遺伝子ベースの治療の台頭
      • CDMOの高い生産能力
    • 抑制要因と課題
      • ATMP生産に関連する人材不足は市場の成長を妨げる可能性が高い
  • PESTEL分析
  • 先進医療用医薬品 CDMO市場フェーズの動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界の先端医療医薬品（ATMP）CDMO市場、適応症別

  • 主な調査結果
  • イントロダクション
  • 腫瘍学
  • 心臓病学
  • 中枢神経系
  • 筋骨格系
  • 感染症
  • 皮膚科
  • 内分泌、代謝、遺伝
  • 免疫学と炎症
  • 眼科
  • 血液学
  • 消化器科
  • その他

第6章 世界の先端医療医薬品（ATMP）CDMO市場、製品別

  • 主な調査結果
  • イントロダクション
  • 細胞治療
  • 遺伝子治療

第7章 世界の先端医療医薬品（ATMP）CDMO市場、フェーズ別

  • 主な調査結果
  • イントロダクション
  • フェーズI
  • フェーズ II
  • フェーズⅢ
  • フェーズ IV

第8章 世界の先端医療医薬品（ATMP）CDMO市場、地域別

  • 主な調査結果
  • イントロダクション
    • 先端医療医薬品（ATMP）CDMO市場評価、地域別、2019-2032年
  • 先端医療医薬品（ATMP）CDMO市場-北米
    • 北米：先端医療医薬品（ATMP）CDMO市場、適応症別、2019～2032年
    • 北米：先端医療医薬品（ATMP）CDMO市場、フェーズ別、2019年～2032年
    • 北米：先端医療医薬品（ATMP）CDMO市場、製品別、2019-2032年
    • 先端医療医薬品（ATMP）CDMO市場-米国
    • 先端医療医薬品（ATMP）CDMO市場- カナダ
  • 先端医療医薬品（ATMP）CDMO市場- 欧州
    • 欧州：先端医療医薬品（ATMP）CDMO市場、適応症別、2019年～2032年
    • 欧州：先端医療医薬品（ATMP）CDMO市場、フェーズ別、2019～2032年
    • 欧州：先端医療医薬品（ATMP）CDMO市場、製品別、2019年～2032年
    • 先端医療医薬品（ATMP）CDMO市場- 英国
    • 先端医療医薬品（ATMP）CDMO市場- フランス
    • 先端医療医薬品（ATMP）CDMO市場- ドイツ
    • 先端医療医薬品（ATMP）CDMO市場- イタリア
    • 先端医療医薬品（ATMP）CDMO市場- スペイン
    • 先端医療医薬品（ATMP）CDMO市場- オランダ
    • 先端医療医薬品（ATMP）CDMO市場- ロシア
  • 先端医療医薬品（ATMP）CDMO市場- アジア太平洋
    • アジア太平洋：先端医療医薬品（ATMP）CDMO市場、適応症別、2019年～2032年
    • アジア太平洋：先端医療医薬品（ATMP）CDMO市場、フェーズ別、2019～2032年
    • アジア太平洋：先端医療医薬品（ATMP）CDMO市場、製品別、2019～2032年
    • 先端医療医薬品（ATMP）CDMO市場- 中国
    • 先端医療医薬品（ATMP）CDMO市場- インド
    • 先端医療医薬品（ATMP）CDMO市場- マレーシア
    • 先進医療用医薬品 CDMO市場- 日本
    • 先端医療医薬品（ATMP）CDMO市場- インドネシア
    • 先端医療医薬品（ATMP）CDMO市場- 韓国
  • 先端医療医薬品（ATMP）CDMO市場-中東およびアフリカ
    • 中東およびアフリカ：先端医療医薬品（ATMP）CDMO市場、適応症別、2019年～2032年
    • 中東およびアフリカ：先端医療医薬品（ATMP）CDMO市場、フェーズ別、2019～2032年
    • 中東およびアフリカ：先端医療医薬品（ATMP）CDMO市場、製品別、2019～2032年
    • 先端医療医薬品（ATMP）CDMO市場- サウジアラビア
    • 先端医療医薬品（ATMP）CDMO市場- アラブ首長国連邦
    • 先端医療医薬品（ATMP）CDMO市場- イスラエル
    • 先端医療医薬品（ATMP）CDMO市場- 南アフリカ
  • 先端医療医薬品（ATMP）CDMO市場-ラテンアメリカ
    • ラテンアメリカ：先端医療医薬品（ATMP）CDMO市場、適応症別、2019-2032年
    • ラテンアメリカ：先端医療医薬品（ATMP）CDMO市場、フェーズ別、2019～2032年
    • ラテンアメリカ：先端医療医薬品（ATMP）CDMO市場、製品別、2019-2032年
    • 先端医療医薬品（ATMP）CDMO市場- メキシコ
    • 先端医療医薬品（ATMP）CDMO市場- ブラジル
    • 先端医療医薬品（ATMP）CDMO市場- アルゼンチン

第9章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • AGC Biologics（Switzerland）
  • Bio Elpida（France）
  • BlueReg（France）
  • Catalent（US）
  • Celonic（Switzerland）
  • CGT Catapult（UK）
  • Lonza（Switzerland）
  • Medicine Patheon（US）
  • Minaris Regenerative（US）
  • Rentschler Biopharma SE（US）
  • WuXi Advanced Therapies（US）
図表

List of Tables

  • Table 1 Global Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 2 Global Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 3 Global Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 4 Advanced Therapy Medicinal Products CDMO Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 6 North America: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 7 North America: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 8 U.S.: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 9 U.S.: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 10 U.S.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 11 Canada: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 12 Canada: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 13 Canada: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 14 Europe: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 15 Europe: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 16 Europe: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 17 UK: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 18 UK: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 19 UK: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 20 France: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 21 France: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 22 France: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 23 Germany: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 24 Germany: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 25 Germany: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 26 Italy: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 27 Italy: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 28 Italy: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 29 Spain: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 30 Spain: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 31 Spain: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 35 Russia: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 36 Russia: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 37 Russia: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 41 China: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 42 China: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 43 China: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 44 India: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 45 India: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 46 India: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 50 Japan: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 51 Japan: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 52 Japan: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 56 South Korea: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 57 South Korea: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 58 South Korea: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 65 UAE: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 66 UAE: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 67 UAE: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 68 Israel: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 69 Israel: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 70 Israel: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 71 South Africa: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 72 South Africa: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 73 South Africa: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 74 Latin America: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 75 Latin America: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 76 Latin America: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 77 Mexico: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 78 Mexico: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 79 Mexico: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 80 Brazil: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 81 Brazil: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 82 Brazil: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • Table 83 Argentina: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • Table 84 Argentina: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • Table 85 Argentina: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Advanced Therapy Medicinal Products CDMO Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Product
  • Figure 7. Global Advanced Therapy Medicinal Products CDMO Market, by Product, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Indication
  • Figure 9. Global Advanced Therapy Medicinal Products CDMO Market, by Indication, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Phase
  • Figure 11. Global Advanced Therapy Medicinal Products CDMO Market, by Phase, 2022 & 2032 (USD Billion)
  • Figure 12. Advanced Therapy Medicinal Products CDMO Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Advanced Therapy Medicinal Products CDMO Market
目次
Product Code: PM4326

The global advanced therapy medicinal products CDMO market size is expected to reach USD 26.27 billion by 2032, according to a new study by Polaris Market Research. The report "Advanced Therapy Medicinal Products CDMO Market Share, Size, Trends, Industry Analysis Report, By Product (Gene Therapy, Cell Therapy, Tissue Engineered, Others); By Phase; By Indication; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The evolution of numerous diseases among the population and the ability to cure chronic health issues with the prevailing medicines is compelling researchers and government institutions to invest in genetic medicine and cell and tissue therapies. This ongoing trend is facilitating a compatible environment for pharmaceutical companies to innovate new therapies, driving the need for organizations that have the required infrastructure for the development, testing, and manufacturing of new therapies, necessitating the assistance of contract development and manufacturing organizations (CDMO).

The rising government initiatives to regulate the pharmaceutical industry are showing a positive impact on the advanced therapy medicinal products CDMO market growth opportunities. In September 2023, UK CDMO Rentschler Biopharma SE received approval to develop and supply adeno-associated virus vectors (AAV) for gene therapy, including bioprocessing and cGMP production, from the Medicines & Healthcare Products Regulatory Agency.

The growing strategic collaborations and partnerships to expand the research and development activities towards treating health problems are positively influencing the ATMP CDMO market. With the Histocell partnership, Reprocell will produce advanced therapies and medicinal products generated from mesenchymal stem cells.

Cell and gene therapy production is showing a positive outlook in the market. According to the Gene, Cell, & RNA Therapy Landscape Report, in Q3 2023, 27 gene therapies, 26 RNA therapies, and 65 non-genetically modified cell therapies, received approval for clinical use. The total number of gene therapies in phase 1 Q3 registered growth by 7% compared to Q1. This trend is demonstrating the potential demand to produce advanced therapeutic medicinal products, boosting the need for CDMO in the coming years.

The tissue engineering industry is gaining momentum in the marketplace, driven by its profound scope in the replacement, repair, and regeneration of tissues, which are used to cure skin, heart, liver, and lung tissue-related health problems. The rising research activities on the development of tissue engineering therapies are expected to drive the advanced therapy medicinal products CDMO market.

Advanced Therapy Medicinal Products CDMO Market Report Highlights

Gene therapy segment is anticipated to witness the highest growth in the coming years due to the increasing clinical trials on gene therapies.

Phase I segment accounted for the largest revenue share, owing to the rise in number of therapeutic developments.

Oncology segment held the largest share, due to the rising number of cancer patients and its varied forms

Asia pacific is projected to register the fastest growth during the forecast period, attributable to the growing investments in cell and gene therapies.

The global players include AGC Biologics, Bio Elpida, BlueReg, Catalent, Celonic, CGT Catapult, Lonza, Medicine Patheon, & Minaris Regenerative.

Polaris Market Research has segmented the advanced therapy medicinal products CDMO market report based on product, phase, indication and region:

Advanced Therapy Medicinal Products CDMO, Product Outlook (Revenue - USD Billion, 2019 - 2032)

  • Cell Therapy
  • Gene Therapy

Advanced Therapy Medicinal Products CDMO, Phase Outlook (Revenue - USD Billion, 2019 - 2032)

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Advanced Therapy Medicinal Products CDMO, Indication Outlook (Revenue - USD Billion, 2019 - 2032)

  • Oncology
  • Cardiology
  • Central nervous system
  • Musculoskeletal
  • Infectious disease
  • Dermatology
  • Endocrine, metabolic, genetic
  • Immunology & inflammation
  • Ophthalmology
  • Hematology
  • Gastroenterology
  • Others

Advanced Therapy Medicinal Products CDMO, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Advanced Therapy Medicinal Products CDMO Market Insights

  • 4.1. Advanced Therapy Medicinal Products CDMO Market - Phase Snapshot
  • 4.2. Advanced Therapy Medicinal Products CDMO Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. The rising cell and gene-based therapies in biotechnology
      • 4.2.1.2. The higher production capability of CDMOs
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. The talent shortage pertaining to ATMP production is likely to impede market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Advanced Therapy Medicinal Products CDMO Market Phase Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Advanced Therapy Medicinal Products CDMO Market, by Indication

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
  • 5.3. Oncology
    • 5.3.1. Global Advanced Therapy Medicinal Products CDMO Market, by Oncology, by Region, 2019-2032 (USD Billion)
  • 5.4. Cardiology
    • 5.4.1. Global Advanced Therapy Medicinal Products CDMO Market, by Cardiology, by Region, 2019-2032 (USD Billion)
  • 5.5. Central nervous system
    • 5.5.1. Global Advanced Therapy Medicinal Products CDMO Market, by Central nervous system, by Region, 2019-2032 (USD Billion)
  • 5.6. Musculoskeletal
    • 5.6.1. Global Advanced Therapy Medicinal Products CDMO Market, by Musculoskeletal, by Region, 2019-2032 (USD Billion)
  • 5.7. Infectious disease
    • 5.7.1. Global Advanced Therapy Medicinal Products CDMO Market, by Infectious disease, by Region, 2019-2032 (USD Billion)
  • 5.8. Dermatology
    • 5.8.1. Global Advanced Therapy Medicinal Products CDMO Market, by Dermatology, by Region, 2019-2032 (USD Billion)
  • 5.3. Endocrine, metabolic, genetic
    • 5.3.1. Global Advanced Therapy Medicinal Products CDMO Market, by Endocrine, metabolic, genetic, by Region, 2019-2032 (USD Billion)
  • 5.4. Immunology & inflammation
    • 5.4.1. Global Advanced Therapy Medicinal Products CDMO Market, by Immunology & inflammation, by Region, 2019-2032 (USD Billion)
  • 5.5. Ophthalmology
    • 5.5.1. Global Advanced Therapy Medicinal Products CDMO Market, by Ophthalmology, by Region, 2019-2032 (USD Billion)
  • 5.6. Hematology
    • 5.6.1. Global Advanced Therapy Medicinal Products CDMO Market, by Hematology, by Region, 2019-2032 (USD Billion)
  • 5.7. Gastroenterology
    • 5.7.1. Global Advanced Therapy Medicinal Products CDMO Market, by Gastroenterology, by Region, 2019-2032 (USD Billion)
  • 5.8. Others
    • 5.8.1. Global Advanced Therapy Medicinal Products CDMO Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Advanced Therapy Medicinal Products CDMO Market, by Product

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • 6.3. Cell Therapy
    • 6.3.1. Global Advanced Therapy Medicinal Products CDMO Market, by Cell Therapy, by Region, 2019-2032 (USD Billion)
  • 6.4. Gene Therapy
    • 6.4.1. Global Advanced Therapy Medicinal Products CDMO Market, by Gene Therapy, by Region, 2019-2032 (USD Billion)

7. Global Advanced Therapy Medicinal Products CDMO Market, by Phase

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
  • 7.3. Phase I
    • 7.3.1. Global Advanced Therapy Medicinal Products CDMO Market, by Phase I, By Region, 2019-2032 (USD Billion)
  • 7.4. Phase II
    • 7.4.1. Global Advanced Therapy Medicinal Products CDMO Market, by Phase II, By Region, 2019-2032 (USD Billion)
  • 7.5. Phase III
    • 7.5.1. Global Advanced Therapy Medicinal Products CDMO Market, by Phase III, By Region, 2019-2032 (USD Billion)
  • 7.6. Phase IV
    • 7.6.1. Global Advanced Therapy Medicinal Products CDMO Market, by Phase IV, By Region, 2019-2032 (USD Billion)

8. Global Advanced Therapy Medicinal Products CDMO Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Advanced Therapy Medicinal Products CDMO Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Advanced Therapy Medicinal Products CDMO Market - North America
    • 8.3.1. North America: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
    • 8.3.2. North America: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
    • 8.3.3. North America: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.3.4. Advanced Therapy Medicinal Products CDMO Market - U.S.
      • 8.3.4.1. U.S.: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.3.5. Advanced Therapy Medicinal Products CDMO Market - Canada
      • 8.3.5.1. Canada: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • 8.4. Advanced Therapy Medicinal Products CDMO Market - Europe
    • 8.4.1. Europe: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.4. Advanced Therapy Medicinal Products CDMO Market - UK
      • 8.4.4.1. UK: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.5. Advanced Therapy Medicinal Products CDMO Market - France
      • 8.4.5.1. France: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.6. Advanced Therapy Medicinal Products CDMO Market - Germany
      • 8.4.6.1. Germany: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.7. Advanced Therapy Medicinal Products CDMO Market - Italy
      • 8.4.7.1. Italy: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.8. Advanced Therapy Medicinal Products CDMO Market - Spain
      • 8.4.8.1. Spain: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.9. Advanced Therapy Medicinal Products CDMO Market - Netherlands
      • 8.4.9.1. Netherlands: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.4.10. Advanced Therapy Medicinal Products CDMO Market - Russia
      • 8.4.10.1. Russia: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • 8.5. Advanced Therapy Medicinal Products CDMO Market - Asia Pacific
    • 8.5.1. Asia Pacific: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.5.4. Advanced Therapy Medicinal Products CDMO Market - China
      • 8.5.4.1. China: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.5.5. Advanced Therapy Medicinal Products CDMO Market - India
      • 8.5.5.1. India: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.5.6. Advanced Therapy Medicinal Products CDMO Market - Malaysia
      • 8.5.6.1. Malaysia: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.5.7. Advanced Therapy Medicinal Products CDMO Market - Japan
      • 8.5.7.1. Japan: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.5.8. Advanced Therapy Medicinal Products CDMO Market - Indonesia
      • 8.5.8.1. Indonesia: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.5.9. Advanced Therapy Medicinal Products CDMO Market - South Korea
      • 8.5.9.1. South Korea: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • 8.6. Advanced Therapy Medicinal Products CDMO Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.6.4. Advanced Therapy Medicinal Products CDMO Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.6.5. Advanced Therapy Medicinal Products CDMO Market - UAE
      • 8.6.5.1. UAE: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.6.6. Advanced Therapy Medicinal Products CDMO Market - Israel
      • 8.6.6.1. Israel: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.6.7. Advanced Therapy Medicinal Products CDMO Market - South Africa
      • 8.6.7.1. South Africa: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
  • 8.7. Advanced Therapy Medicinal Products CDMO Market - Latin America
    • 8.7.1. Latin America: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.7.4. Advanced Therapy Medicinal Products CDMO Market - Mexico
      • 8.7.4.1. Mexico: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.7.5. Advanced Therapy Medicinal Products CDMO Market - Brazil
      • 8.7.5.1. Brazil: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)
    • 8.7.6. Advanced Therapy Medicinal Products CDMO Market - Argentina
      • 8.7.6.1. Argentina: Advanced Therapy Medicinal Products CDMO Market, by Indication, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Advanced Therapy Medicinal Products CDMO Market, by Phase, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Advanced Therapy Medicinal Products CDMO Market, by Product, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AGC Biologics (Switzerland)
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Bio Elpida (France)
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. BlueReg (France)
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Catalent (US)
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Celonic (Switzerland)
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. CGT Catapult (UK)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Lonza (Switzerland)
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Medicine Patheon (US)
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Minaris Regenerative (US)
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Rentschler Biopharma SE (US)
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. WuXi Advanced Therapies (US)
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development